Hyperuricemia-gout, psoriatic disease, and what to expect from advanced anti-obesity therapies

Keywords

psoriasis / psoriatic arthritis / uric acid / hyperuricemia / gout / anti-obesity therapy

References

[1] Toussirot E, Gallais-Sérézal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol. 2022; 13: 970371.

[2] Liu Z, Ma X, Chang T, Yao C, Song M, Biyue S, et al. Associations between psoriasis, psoriatic arthritis and gout or hyperuricemia: A systematic review and meta-analysis. Am J Med Sci. 2025; 369: 671-8.

[3] Chandratre P, Sabido-Sauri R, Zhao SS, Abhishek A. Gout, Hyperuricemia and Psoriatic Arthritis: An Evolving Conundrum. Curr Rheumatol Rep. 2025; 27: 22.

[4] Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al.; ALL-HEART Study Group. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022; 400: 1195-205.

[5] Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al.; FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396: 1745-57.

[6] White WB, Saag KG, Becker MA, Borer JS, Gorelick PB; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018; 378: 1200-10.

[7] Najafi S, Bahrami M, Butler AE, Sahebkar A. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022; 88: 3627-37.

[8] Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018; 20: 1235-45.

[9] Petković-Dabić J, Binić I, Carić B, Božić L, Umičević-Šipka S, Bednarčuk N, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025; 15: 46.

[10] Haran K, Johnson CE, Smith P, Venable Z, Kranyak A, Bhutani T, et al. Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review. Psoriasis (Auckl). 2024; 14: 143-52.